ASND N logo

Ascendis Pharma A/SBMV:ASND N Stock Report

Market Cap Mex$261.9b
Share Price
n/a
1Yn/a
7D0%
1D1.3%
Portfolio Value
​
View

Ascendis Pharma A/S

BMV:ASND N Stock Report

Market Cap: Mex$261.9b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Ascendis Pharma (ASND N) Stock Overview

Operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. More details

ASND N fundamental analysis
Snowflake Score
Valuation3/6
Future Growth6/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Rewards

Trading at 59.3% below our estimate of its fair value

Earnings are forecast to grow 41.68% per year

Earnings have grown 6.5% per year over the past 5 years

Risk Analysis

Negative shareholders equity

Shares are highly illiquid


ASND N Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW441,026 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
441,026 investors already sharing narratives
View all narratives

Ascendis Pharma A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ascendis Pharma
Historical stock prices
Current Share PriceUS$3,851.44
52 Week HighUS$3,881.39
52 Week LowUS$3,476.44
Beta0.49
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO463.07%

Recent News & Updates

Recent updates

Shareholder Returns

ASND NMX BiotechsMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how ASND N performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how ASND N performed against the MX Market.

Price Volatility

Is ASND N's price volatile compared to industry and market?
ASND N volatility
ASND N Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: ASND N's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine ASND N's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20061,189Jan Mikkelsenascendispharma.com

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Ascendis Pharma A/S Fundamentals Summary

How do Ascendis Pharma's earnings and revenue compare to its market cap?
ASND N fundamental statistics
Market capMex$261.93b
Earnings (TTM)-Mex$4.65b
Revenue (TTM)Mex$14.68b
17.8x
P/S Ratio
-56.3x
P/E Ratio

Is ASND N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ASND N income statement (TTM)
Revenue€720.13m
Cost of Revenue€94.92m
Gross Profit€625.22m
Other Expenses€853.25m
Earnings-€228.03m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-3.69
Gross Margin86.82%
Net Profit Margin-31.67%
Debt/Equity Ratio-442.4%

How did ASND N perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/20 10:44
End of Day Share Price 2026/02/20 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ascendis Pharma A/S is covered by 31 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eliana MerleBarclays
Tazeen AhmadBofA Global Research
Michelle GilsonCanaccord Genuity